Status:
RECRUITING
Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsors:
FUJIFILM Toyama Chemical Co., Ltd.
Conditions:
Infectious Disease
Pharmacology
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
FAVIDOSE trial is a Phase I randomized, double blind controlled, monocentric, dose escalation clinical trial. The primary purpose of this trial is to evaluate tolerance of high doses of favipiravir fo...
Eligibility Criteria
Inclusion
- Man between 50 and 75 years old without any desire to have children or woman between 18 and 75 years old ;
- Subject considered healthy after a thorough general examination (questioning, physical examination);
- For men: acceptance of semen collection by masturbation;
- For men: acceptance of condom use from initiation of the investigational drug until 1 month after stopping the investigational drug;
- For women of childbearing potential: effective contraceptive method combining two methods of contraception (one female contraceptive method combined with male condom use) from the inclusion visit until 1 month after discontinuation of the investigational drug;
- Blood chemistry:
- Kalemia, Calcemia, Prothrombin rate (PT), Activated partial thromboplastin time (APTT): values within laboratory normal;
- ALT, ASAT, Uricemia: values below the upper limit of the laboratory normal;
- Other biological results (Blood count; Natremia; Phosphoremia; Chloremia; Fasting blood glucose; Gamma glutamyl transpeptidase; Urea; Total bilirubin; Creatinine; CPK; Lactate dehydrogenase; Albuminemia; Proteinemia; Triglycerides; C-reactive protein; Albumin/Globulin ratio; Alkaline phosphatase) with no clinically significant abnormality.
- NB: A parameter outside the usual values considered clinically significant may, at the investigator's discretion, be tested a second time on another sample taken outside of a visit planned in the protocol before the initiation of the experimental drug.
- Urine dipstick (biochemistry: leukocyturia, proteinuria and hematuria) without clinically significant abnormality;
- Urine tox screen negative (amphetamines/metamphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates);
- Ability to take the investigational drug orally and adherence to the dosage of the investigational drug;
- Acceptance and signing of the informed consent;
- Membership in a social security plan or beneficiary of such a plan;
- Adherence to lifestyle considerations (see section 5.5) during participation in this research.
Exclusion
- Concomitant use or within 15 days prior to inclusion of another QT/QTc prolonging drug or drugs that may disrupt electrolyte levels, among others: loop diuretics, thiazide diuretics and related drugs (see list www.crediblemeds.org)
- History of amiodarone use within 6 months prior to inclusion
- History of gout or current treatment for gout or hyperuricemia
- Treatment with pyrazinamide or any other drug known to induce hyperuricemia
- History of hypersensitivity reaction to a nucleoside analog targeting viral RNA polymerase
- Known hypersensitivity to any of the components (favipiravir or placebo)
- Pregnant or breastfeeding women
- For men: history of vasectomy or known history of infertility.
- Refusal of the subject to complete all the visits, clinical and paraclinical examinations planned by the study
- On ECG: PR \>200ms, QRS \>100ms QTc \>450ms and morphological appearance of abnormal repolarization
- PAS \<100 mmHg
- Any history or active cardiovascular, pulmonary, intestinal, hepatic, renal, metabolic, hematologic, neurologic, bone, joint, muscular, psychiatric, systemic, ocular, gynecologic, andrologic, or infectious disease (including active HIV, HCV, or HBV infection), or any acute condition, which in the judgment of the investigator could be detrimental to the volunteer and/or interfere with or limit the protocol evaluation and data analysis
- Personal or family history of long QT syndrome, torsades de pointes or sudden death
- Patient with severe hepatic impairment
- Gastrointestinal pathology such as ileus, colitis or enterocolitis
- Treatment with another investigational drug or other investigational procedure (clinical trial, clinical investigation of a medical device, category 1 or 2 research involving humans);
- A person who is subject to a legal protection measure (safeguard of justice, curatorship, guardianship);
- Person placed in administrative detention;
- Person who, in the judgment of the investigating physician, may be non-observant during the study, or unable to communicate due to a language barrier or mental disorder
- Person who cannot be contacted in an emergency
- Person with at least one first-degree relative from East Asia or Southeast Asia.
- Secondary Exclusion Criteria
- Participants with at least one of the following criteria will not start the experimental treatment at D1 if they are already randomized:
- Positive nasopharyngeal antigen test for SARS-CoV-2 at D1 (prior to treatment initiation)
- Blood potassium levels outside the normal laboratory range within 8 days prior to treatment initiation (D1)
- ECG: PR \>200ms, QRS \>100ms QTc \>450ms and morphological appearance of abnormal repolarization on Day 1
- Positive pregnancy test on Day 1 (before initiation of treatment)
Key Trial Info
Start Date :
May 14 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT06024421
Start Date
May 14 2024
End Date
November 1 2027
Last Update
May 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Bichat - Claude Bernard
Paris, France, 75018